Acta Haematol

1. BENJAMINI O, Tadmor T, Avigdor A, Gershon R, et al
   Efficacy of preexposure prophylaxis with monoclonal-antibody tixagevimab-cilgavimab against emerging SARS-CoV-2 resistant variants in patients with chronic lymphocytic leukemia.
   Acta Haematol. 2024 Mar 12. doi: 10.1159/000537690.
   

   >> Share

   
   
2. SHAPIRA S, Hirschberger N, Ofran Y, Mizrahi B, et al
   The effect of mind-body intervention on lymphocyte doubling time and treatment free survival in treatment-naive chronic lymphocytic leukemia patients.
   Acta Haematol. 2024 Mar 8. doi: 10.1159/000538055.
   

   >> Share

   
   

   
   Am J Hematol

3. TANG H, Jia W, Jia S, Dong R, et al
   A new chemotherapy-free regimen of olverembatinib in combination with venetoclax and dexamethasone for newly diagnosed Ph+ acute lymphoblastic leukemia: Preliminary outcomes of a prospective study.
   Am J Hematol. 2024 Mar 14. doi: 10.1002/ajh.27289.
   

   >> Share

   
   

   
   Ann Hematol

4. LIU S, Cui Q, Li M, Li Z, et al
   Successful treatment of a B/T MPAL patient by chemo-free treatment with venetoclax, azacitidine, and blinatumomab.
   Ann Hematol. 2024;103:1397-1402.
   

   >> Share

   
   
5. REN Y, Liu F, Chen X, Zhang X, et al
   Decitabine-containing conditioning improved outcomes for children with higher-risk myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation.
   Ann Hematol. 2024;103:1345-1351.
   

   >> Share

   
   
6. LUCERO J, Alhumaid M, Novitzky-Basso I, Capo-Chichi JM, et al
   Flow cytometry-based measurable residual disease (MRD) analysis identifies AML patients who may benefit from allogeneic hematopoietic stem cell transplantation.
   Ann Hematol. 2024;103:1187-1196.
   

   >> Share

   
   

   
   Blood

7. MACK EA, Dougher MC, Ginda AM, Cahill C, et al
   Red cell exchange for rapid leukoreduction in adults with hyperleukocytosis and leukostasis.
   Blood. 2024;143:1049-1054.
   

   >> Share

   
   
8. DIMITRIOU M, Mortera-Blanco T, Tobiasson M, Mazzi S, et al
   Identification and surveillance of rare relapse-initiating stem cells during complete remission post-transplantation.
   Blood. 2023 Dec 14:blood.2023022851. doi: 10.1182/blood.2023022851.
   

   >> Share

   
   
9. AZOULAY E, Maertens J, Lemiale V
   How I manage acute respiratory failure in patients with hematological malignancies.
   Blood. 2024;143:971-982.
   

   >> Share

   
   

   
   BMC Cancer

10. SINGH M, Sharma P, Bhatia P, Trehan A, et al
    Integrated analysis of transcriptome and genome variations in pediatric T cell acute lymphoblastic leukemia: data from north Indian tertiary care center.
    BMC Cancer. 2024;24:325.
    

    >> Share

    
    
11. WANG J, Wang C, Hu A, Yu K, et al
    FLI1 induces erythroleukemia through opposing effects on UBASH3A and UBASH3B expression.
    BMC Cancer. 2024;24:326.
    

    >> Share

    
    

    
    Bone Marrow Transplant

12. NABERGOJ M, Eikema DJ, Koster L, Platzbecker U, et al
    Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
    Bone Marrow Transplant. 2024 Jan 9. doi: 10.1038/s41409-023-02193.
    

    >> Share

    
    
13. ZHANG X, Pang Y, Wei C, Liang D, et al
    Role of allogeneic hematopoietic stem cell transplantation in patients with high-risk T-cell lymphoblastic leukaemia/lymphoma: an analysis of clinical outcomes.
    Bone Marrow Transplant. 2023 Dec 23. doi: 10.1038/s41409-023-02182.
    

    >> Share

    
    

    
    Br J Haematol

14. CHEN N, Pan J, Zhou Y, Mao L, et al
    Gilteritinib-based combination therapy in adult relapsed/refractory FLT3-mutated acute myeloid leukaemia.
    Br J Haematol. 2024;204:861-870.
    

    >> Share

    
    
15. MONTALBAN-BRAVO G, Jabbour E, Borthakur G, Kadia T, et al
    Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents.
    Br J Haematol. 2024;204:898-909.
    

    >> Share

    
    
16. RAVANDI F, Dohner H, Wei AH, Montesinos P, et al
    Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001.
    Br J Haematol. 2024;204:877-886.
    

    >> Share

    
    
17. LU Q, Qu W, Wen Y, Ke P, et al
    Single-cell RNA-seq reveals the links between the metabolic heterogeneity and cell identity in NBM and AML.
    Br J Haematol. 2024;204:1100-1104.
    

    >> Share

    
    
18. CASTANO-DIEZ S, Pomares H, Esteban D, Guijarro F, et al
    Characteristics and long-term outcome in a large series of chronic myelomonocytic leukaemia patients including 104 formerly referred to as oligomonocytic.
    Br J Haematol. 2024;204:892-897.
    

    >> Share

    
    
19. COPLAND M, Ariti C, Thomas IF, Upton L, et al
    A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial.
    Br J Haematol. 2024;204:871-876.
    

    >> Share

    
    
20. LAM SSY, Tsui SP, Fung CY, Saw NY, et al
    Distinct karyotypic and mutational landscape in trisomy AML.
    Br J Haematol. 2024;204:939-944.
    

    >> Share

    
    
21. ZHAO HG
    Should oligomonocytic CMML be classified as an independent disease entity?
    Br J Haematol. 2024;204:749-750.
    

    >> Share

    
    
22. TAN JY, Yeo YH, Tan MC, Chavez JC, et al
    Mortality trends of chronic lymphocytic leukaemia in the United States with the emergence of targeted therapy.
    Br J Haematol. 2024;204:1114-1117.
    

    >> Share

    
    
23. SHIMONY S, Chen EC
    Tri-ing to decipher trisomy AML.
    Br J Haematol. 2024;204:751-752.
    

    >> Share

    
    
24. SUN H, Zhu Y, Li J, Zhao L, et al
    CSF3R P733T is a deleterious germline variant in acute leukaemia showing gain-of-function-like T618I mutation.
    Br J Haematol. 2024;204:e31-e33.
    

    >> Share

    
    
25. NG HL, Robinson ME, May PC, Innes AJ, et al
    Promoter-centred chromatin interactions associated with EVI1 expression in EVI1+3q- myeloid leukaemia cells.
    Br J Haematol. 2024;204:945-958.
    

    >> Share

    
    

    
    Cancer

26. HUANG R, He H, Xu X, Lin X, et al
    Venetoclax plus a hypomethylating agent versus cytarabine, aclarubicin, and granulocyte colony-stimulating factor chemotherapy as a first-line therapy for newly diagnosed acute myeloid leukemia: A propensity score-matched analysis.
    Cancer. 2024 Mar 12. doi: 10.1002/cncr.35278.
    

    >> Share

    
    

    
    Cancer Lett

27. HE Y, Jiang S, Cui Y, Liang J, et al
    Induction of IFIT1/IFIT3 and inhibition of Bcl-2 orchestrate the treatment of myeloma and leukemia via pyroptosis.
    Cancer Lett. 2024 Mar 8:216797. doi: 10.1016/j.canlet.2024.216797.
    

    >> Share

    
    

    
    Eur J Immunol

28. PARVEEN M, Karaosmanoglu B, Sucularli C, Uner A, et al
    Acquired immune resistance is associated with interferon signature and modulation of KLF6/c-MYB transcription factors in myeloid leukemia.
    Eur J Immunol. 2024 Mar 11:e2350717. doi: 10.1002/eji.202350717.
    

    >> Share

    
    

    
    Int J Hematol

29. MAEDA Y
    JSH practical guidelines for hematological malignancies, 2023: I. Leukemia-1. Acute myeloid leukemia (AML).
    Int J Hematol. 2024 Mar 14. doi: 10.1007/s12185-024-03730.
    

    >> Share

    
    
30. SANO H, Fukushima K, Yano M, Osone S, et al
    Analysis of overweight/obese pediatric patients with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 study.
    Int J Hematol. 2024 Mar 9. doi: 10.1007/s12185-024-03745.
    

    >> Share

    
    

    
    J Clin Oncol

31. MAHON FX, Pfirrmann M, Dulucq S, Hochhaus A, et al
    European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission.
    J Clin Oncol. 2024 Mar 12:JCO2301647. doi: 10.1200/JCO.23.01647.
    

    >> Share

    
    
32. LEVIS MJ, Hamadani M, Logan B, Jones RJ, et al
    Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3.
    J Clin Oncol. 2024 Mar 12:JCO2302474. doi: 10.1200/JCO.23.02474.
    

    >> Share

    
    
33. FEDELE PL, Opat S
    Chronic Lymphocytic Leukemia-Time to Care for the Survivors.
    J Clin Oncol. 2024 Mar 15:JCO2302738. doi: 10.1200/JCO.23.02738.
    

    >> Share

    
    

    
    J Virol

34. GUPTA SS, Maetzig T, Maertens GN, Sharif A, et al
    Correction for Gupta et al., "Bromo- and Extraterminal Domain Chromatin Regulators Serve as Cofactors for Murine Leukemia Virus Integration".
    J Virol. 2024 Mar 13:e0013524. doi: 10.1128/jvi.00135.
    

    >> Share

    
    

    
    Leuk Lymphoma

35. ZHU J, Xu M, Ru Y, Gong H, et al
    Comparison of valganciclovir versus foscarnet for the treatment of cytomegalovirus viremia in adult acute leukemia patients after allogeneic hematopoietic cell transplantation.
    Leuk Lymphoma. 2024 Mar 12:1-9. doi: 10.1080/10428194.2024.2321322.
    

    >> Share

    
    

    
    Leuk Res

36. ZHONG S, Kurish H, Walchack R, Li H, et al
    Efficacy and safety of mitoxantrone, etoposide, and cytarabine for treatment of relapsed or refractory acute myeloid leukemia.
    Leuk Res. 2024;139:107468.
    

    >> Share

    
    
37. BOURNE G, Diebold K, Espinoza-Gutarra M, Al-Kadhimi Z, et al
    Addition of single dose gemtuzumab ozogamicin to intensive induction chemotherapy in core-binding factor acute myeloid leukemia.
    Leuk Res. 2024;139:107467.
    

    >> Share

    
    
38. PAN L, Li Y, Gao H, Lai X, et al
    Clinical features and management of germline CEBPA-mutated carriers.
    Leuk Res. 2024;138:107453.
    

    >> Share

    
    
39. SIDI Y, Dong C, Wu Y, Faller DV, et al
    A critical evaluation of the EFS endpoint in AML: Does induction treatment failure timing have a profound impact on study design and results?
    Leuk Res. 2024;138:107465.
    

    >> Share

    
    

    
    Leukemia

40. BONATO A, Chakraborty S, Bomben R, Canarutto G, et al
    NFKBIE mutations are selected by the tumor microenvironment and contribute to immune escape in chronic lymphocytic leukemia.
    Leukemia. 2024 Mar 15. doi: 10.1038/s41375-024-02224.
    

    >> Share

    
    
41. ZACKOVA D, Semerad L, Faber E, Klamova H, et al
    Why are not all eligible chronic myeloid leukemia patients willing to attempt tyrosine kinase inhibitor discontinuation? A Czech nationwide analysis related to the TKI stopping trial HALF.
    Leukemia. 2024 Mar 12. doi: 10.1038/s41375-024-02215.
    

    >> Share

    
    
42. SCHWEDE M, Jahn K, Kuipers J, Miles LA, et al
    Mutation order in acute myeloid leukemia identifies uncommon patterns of evolution and illuminates phenotypic heterogeneity.
    Leukemia. 2024 Mar 11. doi: 10.1038/s41375-024-02211.
    

    >> Share

    
    
43. AKIYAMA H, Zhao R, Ostermann LB, Li Z, et al
    Correction: Mitochondrial regulation of GPX4 inhibition-mediated ferroptosis in acute myeloid leukemia.
    Leukemia. 2024 Mar 8. doi: 10.1038/s41375-024-02202.
    

    >> Share

    
    

    
    Oncol Rep

44. TENG Z, Xu S, Lei Q
    [Retracted] Tanshinone IIA enhances the inhibitory effect of imatinib on proliferation and motility of acute leukemia cell line TIB?152 in vivo and in vitro by inhibiting the PI3K/AKT/mTOR signaling pathway.
    Oncol Rep. 2024;51:66.
    

    >> Share

    
    

    
    PLoS One

45. SWANSON AJ, Rogowski VJ, Bishop JA, Walker DM, et al
    CLEC11A methylation is correlated to AML subtypes and cytogenetic risk factors but not patient demographics.
    PLoS One. 2024;19:e0300477.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share